TransMedics Group (FRA:8T8) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8T8 TransMedics Group Inc FRA:8T8
71 GF Score
Price €61.50
GF Value €145.03
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is TransMedics Group FFO per Share?

FFO per Share only applies to REITs.

FRA:8T8
71GF Score
TransMedics Group Inc FRA:8T8
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is TransMedics Group (FRA:8T8) Overvalued in 2026?

Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued. The current stock price of €61.50 is trading 57.6% below its estimated GF Value™ of €145.03. GuruFocus considers TransMedics Group to be Possible Value Trap.

Key valuation signals for FRA:8T8:

  • FFO per Share:
  • GF Value™: €145.03 vs. price of €61.50 (57.6% below fair value)
  • GF Score™: 71/100 with 9 warning signs

No single metric tells the full story. See the FRA:8T8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TransMedics Group Business Description

Address 200 Minuteman Road, Andover, MA, USA, 01810
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
71GF Score

Get the complete analysis for FRA:8T8

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€61.50
Price
€145.03
GF Value